Agenus | AGEN - Cost Of Sales


Agenus reported $137K in Cost of Sales for its fiscal quarter ending in March of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Agenus USD 137K 19K Mar/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
CSL USD 1.79B 2.15B Jun/2025
Dynavax Technologies USD 14.4M 368K Sep/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
Incyte USD 121.18M 22.18M Dec/2025
Intrexon USD 1.01M 344K Jun/2024
J&J USD 7.97B 689M Dec/2025
Jiangsu Hengrui CNY 1.08B 34.18M Sep/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
MacroGenics USD 44.3M 5.4M Sep/2025
Merck EUR 2.1B 123M Sep/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Novavax USD 60.62M 91.77M Sep/2024
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Veracyte USD 41.21M 196K Sep/2025